Market News & Trends
TNF Inhibitors Lay Groundwork for Next-Generation of Disease-Modifying Anti-Rheumatic Drugs
The challenges inherent in the pharmacological management of rheumatic diseases have stoked huge demand for drug classes with excellent safety and efficacy profiles. While tumor…
12/12/2012
TNF Inhibitors Lay Groundwork for Next-Generation of Disease-Modifying Anti-Rheumatic Drugs The challenges inherent in the pharmacological management of rheumatic diseases have stoked huge demand for…
Isis Pharmaceuticals Announces $31-Million Strategic Cancer Alliance
Isis Pharmaceuticals, Inc. and AstraZeneca recently announced a strategic alliance for the discovery and development of novel-generation antisense therapeutics against five cancer targets, which includes…
Moderna Therapeutics Secures $40 Million for New Way of Making Therapeutic Proteins
Moderna Therapeutics recently announced it has closed more than $40 million in financing to date, led by Flagship Ventures and private investors, which will be…
12/5/2012
Curis Announces Several Major Announcements Curis, Inc. recently announced it has licensed from Genentech, a member of the Roche Group, exclusive worldwide rights for the…
Curis Announces Several Major Announcements
Curis, Inc. recently announced it has licensed from Genentech, a member of the Roche Group, exclusive worldwide rights for the development and commercialization of GDC-0917,…
Governor Jindal, AgraTech International Announce New Chitosan Facility
Governor Bobby Jindal and AgraTech International Inc. Chairman Richard DeMarco recently announced the company will renovate a former Opelousas bottling facility, creating 50 new direct…
Hovione & Solvias Announce Drug Solubility Collaboration
Hovione and Solvias recently announced the establishment of a collaboration focused on the development and GMP supply of pharmaceutical co-crystals. This strengthens Hovione's expertise and…
New Technology for Producing Thermostable Vaccines
Bend Research Inc., PATH, and Fraunhofer USA Center for Molecular Biotechnology (FhCMB) recently announced the development of a new technology for the production of thermostable…
Selecta Biosciences & Sanofi Sign Global Collaboration
Selecta Biosciences, Inc. recently announced it has entered into a strategic global collaboration with Sanofi to discover highly targeted, antigen-specific immunotherapies for life-threatening allergies. Under…
Tekmira Acquires Worldwide License to Novel RNAi Technology
Tekmira Pharmaceuticals Corporation recently announced it has obtained a worldwide, non-exclusive license to a novel RNAi payload technology called Unlocked Nucleobase Analog (UNA) from Marina…
Teva to Focus on Smaller M&A
Teva Pharmaceutical Industries Ltd. is shifting away from the multi-billion dollar acquisitions that have defined its growth for the past decade, indicating acquisitions don't have…
XOMA Corporation Seeks to Sublicense Drug
XOMA Corporation recently announced the 837-patient Phase III PATH trial (Perindopril Amlodipine for the Treatment of Hypertension) has demonstrated the fixed-dose combination (FDC) of perindopril…
11/28/2012
CoreRx & ViroPro Announce Agreement CoreRx, Inc. and Viropro, Inc. recently announced the two companies have entered into a Reciprocal Referral Agreement. The Agreement will…
BASF Plans to Acquire Pronova BioPharma
BASF recently announced it plans to acquire Pronova BioPharma ASA, Lysaker, Norway, a pioneer in the field of research, development, and manufacturing of omega-3 fatty…
CoreRx & ViroPro Announce Agreement
CoreRx, Inc. and Viropro, Inc. recently announced the two companies have entered into a Reciprocal Referral Agreement. The Agreement will benefit both companies' existing and…
Genzyme Corporation Announces Drug Approval
Genzyme, a Sanofi company, recently announced that the Australian Therapeutic Goods Administration (TGA) has approved AUBAGIO (teriflunomide) 14 mg as a new once-daily, oral treatment…
MethylGene Closes Substantial Private Placement
MethylGene Inc. recently announced it has completed its previously announced private placement of 179,690,970 units at a subscription price per unit of Cdn.$0.145 (the Subscription…
11/21/2012
Innovative Drugs to Transform Alzheimer's Disease Medication Market The patent expiry of all four existing EMEA-approved drugs for Alzheimer's disease (AD) by 2015 is likely…
Allergan to Acquire SkinMedica for $350 Million
Allergan, Inc. recently announced it has entered into a definitive agreement with SkinMedica, Inc. to acquire the privately held company's topical aesthetics skin care…
